NCT05305066 Stand UP to Rheumatoid Arthritis (SUPRA)
| NCT ID | NCT05305066 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Marie Hudson, MD |
| Condition | Rheumatoid Arthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2023-02-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2023-02-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Rheumatoid arthritis is a disabling arthritis that affects young women disproportionately. Although the physicians have some excellent treatments, they do not know which treatment is best for which patient. The investigators want to find ways to identify the right drug for the right patient at the right time. This is what personalized medicine is all about.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years; * Arthritis that fulfills the 2010 ACR/EULAR classification criteria for RA; * Failure to standard conventional synthetic DMARDs and eligible for second-line b/tsDMARDs (Sub-study 1) or failure to at least one TNF inhibitor and eligible for third-line b/tsDMARDs (Sub-study 2). Exclusion Criteria: * Prior b/tsDMARDs for Sub-study 1 or prior b/tsDMARDs other than TNF inhibitors for Sub-study 2; * Contraindication to b/tsDMARD therapy, such as active infection or untreated latent TB, current malignancy, severe organ dysfunction, history of VTE (unless anticoagulated), high risk of cardiovascular disease, pregnancy/lactation; * Overlap with another inflammatory disease requiring specific immunosuppressive therapy, such as lupus nephritis; * Unable to provide consent or complete forms (alone or with assistance) in English or French
Contact & Investigator
Marie Hudson, MD
PRINCIPAL INVESTIGATOR
Sir Mortimer B. Davis - Jewish General Hospital
Frequently Asked Questions
Who can join the NCT05305066 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rheumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05305066 currently recruiting?
Yes, NCT05305066 is actively recruiting participants. Contact the research team at marie.hudson@mcgill.ca for enrollment information.
Where is the NCT05305066 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT05305066 clinical trial?
NCT05305066 is sponsored by Marie Hudson, MD. The principal investigator is Marie Hudson, MD at Sir Mortimer B. Davis - Jewish General Hospital. The trial plans to enroll 75 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.